Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904862 | 0.76 | MAPT (0.38) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL24292408 | 0.76 | SMPD3 (0.33) | ALOX15 | |
| SCHEMBL24737152 | 0.74 | NOS1 (0.41) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL24813878 | 0.74 | MAPT (0.36) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL26083604 | 0.74 | NOS1 (0.41) | MAPTRAB9ANPC1ATMSMN1; SMN2 | |
| SCHEMBL26846624 | 0.73 | — | — | |
| SCHEMBL21570498 | 0.73 | KDM4E (0.33) | L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL2528824 | 0.71 | PRMT6 (0.38) | MAPTRAB9ANPC1HTTNPSR1 | |
| SCHEMBL5139434 | 0.71 | ALDH1A1 (0.37) | SMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL20483217 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475644-B1 | HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2014-01-08 | — | — | EP | claimed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023205778-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| WO-2023078271-A1 | AROMATIC COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 上海旭成医药科技有限公司 | 2023-05-11 | — | — | WO | disclosed |
| WO-2023072301-A1 | PYRAZOLO[3,4-D]PYRIMIDIN-3-ONE COMPOUND AND MEDICAL USE THEREOF | 正大天晴药业集团股份有限公司 | 2023-05-04 | — | — | WO | disclosed |
| EP-3888749-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2021-10-06 | — | — | EP | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-10927111-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2020-11-05 | — | — | US | disclosed |
| EP-3578547-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2019-12-11 | — | — | EP | disclosed |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | INFLAZOME LIMITED (IE) | 2018-02-15 | — | — | US | disclosed |
| WO-2017176836-A1 | COMPOSITIONS AND METHODS FOR CONTROLLING FECUNDITY OF ARACHNIDA SPECIES | FMC CORPORATION (US) | 2017-10-12 | — | — | WO | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347052-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | MAPT 3066/4885RAB9A 844/4885NPC1 1495/4885 |
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | MAPT 3066/4885RAB9A 844/4885NPC1 1495/4885 |
| US-10927111-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | MAPT 3066/4885RAB9A 844/4885NPC1 1495/4885 |
| US-20230365592-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | MAPT 2359/4885RAB9A 1335/4885NPC1 3526/4885 |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | MAPT 3066/4885RAB9A 844/4885NPC1 1495/4885 |
| US-20180044287-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | NLRP3, PYCARD, IAPP | MAPT 1672/4885RAB9A 3614/4885NPC1 799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.